Company Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases.
It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer.
It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer.
The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer.
UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
| Country | United States |
| IPO Date | May 4, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 217 |
| CEO | Elizabeth A. Barrett |
Contact Details
Address: 400 Alexander Park Princeton, New Jersey United States | |
| Website | https://www.urogen.com |
Stock Details
| Ticker Symbol | URGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001668243 |
| CUSIP Number | M96088105 |
| ISIN Number | IL0011407140 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Elizabeth A. Barrett | President, Chief Executive Officer & Director |
| Christopher Degnan CPA | Chief Financial Officer |
| Bryon Wornson | Executive Vice President of Talent, Advocacy & Communications |
| Dr. Marina Konorty Ph.D. | Executive Vice President of Research & Development and Technical Operations |
| Dr. Mark P. Schoenberg M.D. | Chief Medical Officer |
| Dr. Polly A. Murphy D.V.M., M.B.A., Ph.D. | Chief Business Officer |
| James Ottinger R.ph. | Executive Vice President of Regulatory Affairs & Quality |
| Jason Drew Smith J.D. | General Counsel, Chief Compliance Officer & Corporate Secretary |
| Michael J. Louie M.D., M.P.H., M.Sc. | Senior Vice President of Medical Affairs & Clinical Development |
| Vincent I. Perrone | Senior Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | SC 13D/A | [Amend] Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 06, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |